Diabetes medications with cardiovascular protection – what now after LEADER®? Could metformin, pioglitazone, empagliflozin and liraglutide complement each other to save lives?

Most read articles by the same author(s)

• Ken y Thong, Piya S Gupta, Melissa L Cull, Karen A Adamson, David S Dove, Susannah V Rowles, Stephanie Tarpey, Catriona Duncan, John Chalmers, Roy Harper, Paula Mcdonald, Ursula Brennan, Chris Walton, Robert EJ Ryder, GLP-1 receptor agonists in type 2 diabetes - NICE guidelines versus clinical practice , British Journal of Diabetes: Vol. 14 No. 2 (2014)
• Tom Crabtree, Karen Adamson, Alex Bickerton, Alison Evans, Suzanne Phillips, Alison Gallagher, Niels Larsen, Dennis Barnes, Ketan Dhatariya, Benjamin CT Field, Iskander Idris, Robert EJ Ryder, The factors predicting glucose and weight response to injectable semaglutide (Ozempic): real-world data from the Association of British Clinical Diabetologists’ audit programme , British Journal of Diabetes: Vol. 23 No. 2 (2023): December 2023
• Robert EJ Ryder, Ralph A Defronzo, Diabetes medications with cardiovascular protection in the wake of EMPA-REG OUTCOME: the optimal combination may be metformin, pioglitazone and empagliflozin , British Journal of Diabetes: Vol. 15 No. 4 (2015)
• Thomas SJ Crabtree, Ralph A DeFronzo, Robert E J Ryder, Clifford J Bailey, Imeglimin, a novel, first in-class, blood glucose-lowering agent: a systematic review and meta-analysis of clinical evidence , British Journal of Diabetes: Vol. 20 No. 1 (2020): June 2020
• Dinesh Nagi, Robert EJ Ryder, Yue Ruan, Benjamin CT Field, Parth Narendran, Rajiv Gandhi, Sophie Harris, Kinga A Várnai, Jim Davies, Sarah H Wild, Emma G Wilmot, Kamlesh Khunti, Rustam Rea, An audit of people admitted to hospital with diabetes and coronavirus (SARS-CoV-2): data collection methods. The Association of British Clinical Diabetologists (ABCD) Nationwide Audit , British Journal of Diabetes: Vol. 21 No. 1 (2021): June 2021
• Ken Y Thong, Barbara M Mcgowan, Thein Htay, Andrew Pernet, Chris Kelly, Chinnadorai Rajeswaran, Jill Howell, Catriona Duncan, Berit Inkster, Linda Buchanan, Saiful Kassim, Rahul Nayer, Nicholas D Barwell, Christopher Walton, Robert EJ Ryder, ABCD Nationwide Liraglutide Audit contributors, Insulin treatment and longer diabetes duration both predict poorer glycaemic response to liraglutide treatment in type 2 diabetes: the Association of British Clinical Diabetologists Nationwide Liraglutide Audit , British Journal of Diabetes: Vol. 15 No. 4 (2015)
• Robert EJ Ryder, Ralph A Defronzo, What now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement each other to save lives? , British Journal of Diabetes: Vol. 17 No. 3 (2017)
• David M Williams, Jim Davies, Benjamin CT Field, Rajiv Gandhi, Sophie Harris, Kamlesh Khunti, Dinesh Nagi, Parth Narendran, Rustam Rea, Yue Ruan, Robert EJ Ryder, Kinga A Várnai, Sarah H Wild, Emma G Wilmot, Thinzar Min, Julia Platts, Richard Chudleigh, Jeffrey W Stephens, Sam Rice, COVID-19 outcomes in people with diabetes in Wales: a secondary analysis of the ABCD audit , British Journal of Diabetes: Vol. 21 No. 2 (2021): December 2021
• Robert EJ Ryder, Susan P Irwin, Wyn Burbridge, Hardeep Gandhi, Tahira Bashir, Rachael A Allden, Mordel Wilson, Melanie Wyres, Melissa Cull, Mahi Yadagiri, John P Bleasdale, Edward N Fogden, Mark R Anderson, Piya Sen Gupta, The United Kingdom's first NHS Endobarrier service for advanced diabesity: 1-year outcomes for all 62 treated patients , British Journal of Diabetes: Vol. 19 No. 2 (2019): DECEMBER 2019
• Bob Ryder, Ralph A DeFronzo, Diabetes medications with cardiovascular protection in the wake of EXSCEL: is there a class effect for long-acting GLP-1 receptor agonists? , British Journal of Diabetes: Vol. 17 No. 4 (2017)